A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.

NCT ID: NCT00236782

Last Updated: 2011-06-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1517 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-10-31
• Study Completion Date: 1999-03-31

Brief Summary

The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Mercilon.

Detailed Description

This is an open-label, multicenter, international study to evaluate the contraceptive efficacy, safety, cycle control, compliance, and subject satisfaction of the transdermal patch compared with Mercilon. Fourteen hundred healthy women will receive study medication for either 6 or 13 cycles. The first 265 transdermal patch subjects and the first 200 Mercilon subjects will be expected to complete 13 cycles of medication. All subsequent subjects will be expected to complete 6 cycles. The ratio of subjects assigned to the transdermal patch arm of the study and to the Mercilon arm will be 4:3. At admission (Visit 1) study drug, diary cards and subject instructions for Cycle 1 and replacement patches for Cycles 1 to 6 are dispensed. The first patch will be applied and Mercilon pill will be taken on the first day of menses. Study medication and diary cards will be issued on day 28 of Cycles 1 (Visit 2) and 3 (Visit 3), and those continuing for 13 cycles will receive study drug again on day 28 of Cycles 6 (Visit 4) and 9 (Visit 5). Diary cards and empty medication packages will be collected at every visit. Final visits are on day 28 of Cycles 6 and 9. Diary card information was used to record compliance and bleeding information (to assess cycle control). Contraceptive efficacy was assessed by means of the Pearl Index and life table analysis (gross cumulative probability of pregnancy). Safety evaluations were based on adverse events, which were collected throughout the study, and changes in gynecologic examinations, vital signs, and laboratory results from prestudy to final visit. A transdermal patch, containing 6 mg NGM and 0.75 mg EE, delivering 250 ug NGM and 25 ug EE over 24 hours for 7 days, is worn for 1 week and replaced for 3 consecutive weeks.The fourth week is patch-free. A Mercilon pill is taken for 21 consecutive days followed by a 7-day pill-free week.

Conditions

Contraception

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

norelgestromin + ethinyl estradiol; mercilon

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy women with regular menstrual cycles
• sexually active and at risk of pregnancy
• nonpregnant
• acceptable body mass index (BMI)
• last term pregnancy at least 42 days prior, nonlactating, with 1 normal menstrual cycle since
• sitting BP<140mmHg/<90mmHg
• 1 normal menstrual cycle since removal of IUD or norplant
• agreement to use study drug for contraception for up to 13 cycles, except when backup contraception is required for disease protection or patch detachment
• agree not to use other systemic steroid medication
• signed Informed Consent Form.

Exclusion Criteria

• Presence, history, hereditary predisposition or risk of deep vein thrombophlebitis or thromboembolic disorders
• cerebral vascular or coronary artery disease, hypertension, or severe migraines
• liver tumor resulting from estrogen-containing products
• diabetes mellitus
• cholestatic jaundice, liver or renal disease
• neurovascular lesion of the eye or serious visual disturbance
• abnormal PAP smear
• undiagnosed abnormal vaginal bleeding
• thyroid disorder
• dermal hypersensitivity
• carcinoma of breast, endometrium or other estrogen-dependent neoplasia
• substance abuse
• received experimental drug or any hepatic enzyme-inducing drugs within prior 30 days
• received any depot hormone injection within prior 6 months
• smoking women over 35 years of age.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

Sponsor Role: lead

Principal Investigators

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial

Role: STUDY_DIRECTOR

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

References

Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002 Feb;77(2 Suppl 2):S13-8. doi: 10.1016/s0015-0282(01)03275-7.

Reference Type: RESULT

PMID: 11849631 (View on PubMed)

Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril. 2002 Feb;77(2 Suppl 2):S32-5. doi: 10.1016/s0015-0282(01)03262-9.

Reference Type: RESULT

PMID: 11849634 (View on PubMed)

Related Links

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=660&filename=CR005503_CSR.pdf

A study of efficacy and safety with the transdermal contraceptive system versus Mercilon.

Other Identifiers

CR005503

Identifier Type: -

Identifier Source: org_study_id